The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
After reading this again
“.....additional funding during the period, which will be deployed to advance these programmes into clinical development and build a robust data package to support our ongoing partnering activities for these exciting and differentiated assets."
Looks like we are going alone.......which is a departure from the business plan.
IMHO the term “ differentiated” relates to no toxicity at high dose levels unlike other kinase inhibitors
GLA
Back to Q1 2022 for SDC-1801 phase 1 trials.......CTA before Christmas.....back to waiting and anticipating (all long haulers are familiar with this)
Covid trials could be notified at anytime though.
Cash in the bank and a decent payday for the board.......they may load up with a few cheap shares....lol
No bad news and a little bit ‘vanilla’
GLA
Frustratingly the word count cut the last few characters off the link.
Yes the last sentence is very relevant - SDC-1801 is very selective and considered ‘cleaner’ than other kinase inhibitors.
https://www.nature.com/articles/s41392-021-00679-0
GLA - tyk tock tyk tock.......only a matter of time.
Hi All
Interesting research paper published by ‘nature’ (07 July 2021) about cytokine storms (CS) resulting from covid infection and possible therapeutics. Baricitinib is covered in the paper. Of interest is our POC experiments funded by UKRI that concluded our SDC-1801 as a similar profile to Baricitinib.
Hoang et al. found that baricitinib treatment significantly improved the inflammatory condition in SARS-CoV-2-infected rhesus macaque (lab monkeys), as manifested by reduced inflammatory cell infiltration and neutrophil recruitment; limited lung pathology; and suppressed expression of pro-inflammatory mediators in lung macrophages. Baricitinib has also been evaluated in a series of clinical trials. An observational, longitudinal trial including 76 COVID-19 patients showed that compared with the control group (n?=?56), patients in the baricitinib group (n?=?20) presented remarkably reduced serum levels of IL-6, IL-1ß, and TNF-a; accelerated recovery of blood T and B cell counts; increased production of antibodies against SARS-CoV-2. Another observational cohort study from Spain showed that baricitinib improved lung function in patients with moderate-to-severe COVID-19.
Interestingly, existing studies showed that besides the acknowledged inhibitory effects on CS, baricitinib can also dampen ACE2-mediated SARS-CoV-2 endocytosis by inhibiting AP2-associated protein kinase 1 and cyclin G-associated kinase, which serves as another mechanism of its action in COVID-19. Moreover, several other reports have also been published and numerous clinical trials of baricitinib are registered at ClinicalTrials.gov to evaluate its clinical effects in severe COVID-19.
In addition, several other clinical trials for ruxolitinib evaluation and six clinical trials that are evaluating the administration of tofacitinib in COVID-19 patients have been registered at ClinicalTrial.gov
Despite these promising clinical data, JAKinibs should be used with caution because of their side effects, based on the following considerations: nonselective inhibition of the JAK/STAT pathway increases the risk of secondary infection such as herpes zoster virus reactivation given its general inhibitory effects on multiple aspects of physiological actions, including the innate immune system.
In addition, considering the general immunosuppressive nature, some researchers are concerned that continuous treatment with JAKinibs for autoimmune diseases may increase the risk of SARS-CoV-2 infections or contribute to poor outcomes in COVID-19.
The FDA has warned that administration of some JAKinibs has increased the risk of thrombosis.
Thus, developing JAKinibs with better specificity could be a future direction of research aimed to prevent/reduce CS and improve the survival of COVID-19 patients.
Yes the last sentence is very relevant - SDC-1801 is very selective and considered ‘cleaner’ than other kinase inhibitors.
https://www.nature.com/articles/s41392-021-0067
Hi BoIlB
You may be on to something there.......the language used in the below extracts is very similar:
Sareum RNS from 01 July
‘The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field’.
From the WHO announcement 11 August
The World Health Organization (WHO) has announced the next phase in its Solidarity trial: Solidarity PLUS will enroll hospitalized patients to test three new drugs in hospitalized COVID-19 patients.
These therapies.........were selected by an independent expert panel for their potential in reducing the risk of death in hospitalized COVID-19 patients.
Maybe SDC-1801 could be under review now by said ‘experts’ ready for the next rollout into Solidarity.
GLA
Considering we are over the midpoint of Q3, as others have raised, the next few weeks should be ‘news’ rich!
Add to this other pipeline news (secret patent, SDC-1802 ‘associated’ patent, SRA737 restart/on license/combo trial news, covid trials) and we could be at a whole new level with any of these.
Hold for Gold
Hi All
The latest series of RNS’s from SAR following the multi million pound investment from HNWI’s gave a revised timetable of ‘Q3’ for SDC-1801 to get into the clinic and phase 1 trials. With SDC-1802 not being far behind. You will note I don’t mention the covid play - just the routes the drugs have been developed for.
TM has been burnt previously on missing dates so would have been confident on issuing this revised Q3 runway. Prior to the recent investments the timeline was pushed out to Q1 2022 which is 1 year behind schedule as we should have been in the clinic Q1 2021 (as per 2020 news flows) but that was subject to funding and covid delays......the funding is now sorted, may still be subject to covid delays though.
The new investors have clearly been shown data that made them confident of future returns.
Only now a matter of time, we have been here long enough to know and in reality could have only ever dreamed of what has actually unfolded in the last 6 weeks.
GLA
Hi All
The below link is to a peer reviewed research paper published in the Journal of Infection on the 08 August 2021.
In summary, it infers that delta can bypass the vaccines currently in use as these were obviously developed from the original Wuhan variant. Its findings show that delta can undermine the efficacy of the current global vaccine programme and that 2nd generation vaccines should now be considered.
It has already been shown that fully vaccinated people can get reinfected with Delta and further pass it on.
https://www.journalofinfection.com/article/S0163-4453(21)00392-3/fulltext#relatedArticles
Stay safe
Agree it’s a good article and up to date but it’s only the local ‘Cambridge’ business forum, would get more impact on Monday if it was the FT or Wall St Journal.......like they say though, any news/PR is good.
GLA
Oregon will send at least 500 National Guard troops to help hospitals with a flood of Covid patients amid its largest wave of cases of the pandemic. "The harsh and frustrating reality is that the Delta variant has changed everything," Gov. Kate Brown said
Hi Jiffy
There is enough room in the autoimmune market for multiple therapeutics. I’m not 100% on the efficacy of these three mentioned or the relevant toxicity.
Remember, covid therapeutics is a side play (right now) for SAR and according to Larry Brilliant the pandemic is only just getting going. Approx 206M cases recorded to date out of a global population of over 7 billion. Developed countries are making progress to get on top of the virus but with new variants the efficacy of vaccines will likely become an issue. It’s a race between vaccines and variants hence the requirements for boosters already. The less developed nations are only just seeing rising cases this year in particular African countries.
Long way to go and like I say the market for covid therapeutics will be large enough for many options - just like the vaccines, four or five in EUA with reported global shortages, but over 90+ Covid vaccines under development.
SAR is not a ‘one trick pony’ and the HNWI investors know this.
Kick back, relax and Hold for Gold. As TM always claimed - “not first in class but best in class’
ATB
Hi Afham and Citizen
I’m sure that SAR would have already paid the $600 to the patent office, so news of this ‘association’ will become evident very soon.
As we know, the SKIL is full of candidates and I’m expecting our genius has tweaked another molecule to fit the current requirements.......
All upside
Hold for Gold
Hi Blackie
Confidence is high......you don’t issue statements of being superior to dexamethasone without a plan to move it forward.
Won’t be long now and all the pieces will be in play and the rerate to an appropriate level will be seen.
GLA
Bodes well.......no doubters hanging around, they realise now it was a pointless mission to deramp the sp as the real sentiment is being witnessed through the £4.5M investment to date.........
All upside and we wait as patient as ever!
Hold for Gold
We must be very close to being selected for trials......at the start of the pandemic, I predicted that all existing drug candidates would be trialled before novel candidates.
A clinical trial in 52 countries will study three anti-inflammatory drugs as potential treatments for COVID-19 patients, the World Health Organisation said today.
"These therapies - artesunate, imatinib and infliximab – were selected by an independent expert panel for their potential in reducing the risk of death in hospitalised COVID-19 patients," it said in a statement.
Artesunate is already used for severe malaria, while imatinib is used to treat certain cancers, and infliximab treats diseases of the immune system such as Crohn's Disease and rheumatoid arthritis.
WHO-led trial to study three anti-inflammatory drugs for COVID-19 patients | Reuters
GLA
Hi All - after what could be argued as the worlds best response to covid by vaccine rollout, rising cases in fully vaccinated people is rising.
As a result, Israel's government has introduced a raft of new coronavirus restrictions, including sweeping implementation of a digital vaccine passport and tighter restrictions on mass gatherings, as the country struggles with skyrocketing new infections.
The country had appeared to have put the coronavirus pandemic behind it a few months ago after a world-leading vaccine drive but it is now re-imposing regulations in a bid to clamp back down on infections.
The cabinet gave its approval for the tighter measures — including limitations on people gathering indoors and restricting entry to venues and restaurants to "Green Pass" holders — as new cases of the highly infectious delta variant of the coronavirus surge despite widespread vaccination against COVID-19.
Israeli Prime Minister Naftali Bennett said the government would be "giving a booster" to the country’s healthcare system as new coronavirus cases continue a precipitous climb.
He said Israel had to prepare for a situation of mass hospitalisations, and was allocating 2.5 billion shekels ($774 million) to help boost capacity at hospitals nationwide.
Despite its vaccination campaign, Israel has seen new coronavirus cases rise in recent weeks.
The health ministry recorded 5,755 new cases on Wednesday, the highest daily figure since February, and serious cases have grown from 19 in mid-June to 400.
Over 58% of the country’s 9.3 million citizens have received two doses of the Pfizer/BioNTech vaccine.
Earlier this month Israel started giving third vaccine doses to immunosuppressed individuals and citizens over the age of 60.
Covid is going no where
Stay safe